1. Market Research
  2. > Healthcare Market Trends
Global Human Microbiome Market Size, Share & Industry Trends Analysis Report By Product, By Disease Type, By Technology, By Application, By Type, By Regional Outlook and Forecast, 2022 – 2028

Global Human Microbiome Market Size, Share & Industry Trends Analysis Report By Product, By Disease Type, By Technology, By Application, By Type, By Regional Outlook and Forecast, 2022 – 2028

  • May 2022
  • 296 pages
  • ID: 6289257
  • Format: PDF
  • KBV Research


Table of Contents

The Global Human Microbiome Market size is expected to reach $1.1 billion by 2028, rising at a market growth of 32.2% CAGR during the forecast period.

The human microbiome is made up of all microbes found on or in human tissues and biofluids, as well as the anatomical places where they live, such as the skin, seminal fluid, mammary glands, uterus, ovarian follicles, saliva, oral mucosa, biliary tract, conjunctiva, and gastrointestinal tract. Bacteria, archaea, fungus, protists, and viruses are all examples of the human microbiota. Despite the fact that micro-animals can survive on humans, they are usually excluded from this description. The term human microbiome is sometimes used in genomics to refer to the aggregate genomes of resident bacteria. Human metagenome, on the other hand, has the same connotation.

Bacteria, viruses, archaea, and eukaryotes live both inside and outside of human bodies, making up the human microbiome. These organisms have an impact on human physiology in both health and disease, enhancing or inhibiting metabolic and immunological systems. Microorganisms colonize diverse areas on and inside the human body, adapting to the unique characteristics of each niche. The gastrointestinal tract is dominated by facultative anaerobes, whereas the nasal cavity, respiratory tract, and skin surface are dominated by strict aerobes. Because of the biological connection of the organisms with the immune system throughout time, the indigenous organisms inside the human body are well adapted to the immune system. Human health and disease etiology are both influenced by changes in the gut microbial flora. These changes are caused by lifestyle choices and the prevalence of an illness. Dysbiosis makes the host more vulnerable to infection, the type of which varies on the anatomical place. The precise metabolic activities and functions of these microorganisms within each bodily location are compensated by the inherent diversity of the human microbiota. As a result, it’s critical to comprehend the human microbiome’s microbial composition and behaviors as they relate to health and disease.

COVID-19 Impact

The COVID-19 pandemic significantly impacted various businesses all over the world. Several developed, developing, and under-developed economies were also demolished due to the advent of the COVID-19 pandemic. In addition, to regulate the rapid diffusion of the infection, governments all over the world enforced stringent lockdown in their countries. The imposition of lockdown across countries resulted in a temporary closure of various companies, businesses, and manufacturing units of several goods and services. Moreover, as a result of government-imposed travel restrictions, the global supply chain was also disrupted. Further, the healthcare sector of all the countries across the world was devastated, which placed a massive burden on researchers and scientists.

Market Growth Factors

Rising focus on the development of therapeutics

The efficiency of medicinal drugs is significantly influenced by the microbiome of the human gut. Several studies have demonstrated that the appropriate balance of microorganisms in the human body can help treat a variety of ailments over time. This link between bacteria and specific diseases may open up new possibilities for drug developers (or vaccine manufacturers). Because microbes are rich in enzymes, they can be exploited in a variety of therapeutic applications, including the search for new medicines. Microbiome therapy has grown in popularity in recent years. The National Institutes of Health (NIH) spent USD 215 million on the Human Microbiome Project (HMP) along with USD 728 million on extramural human microbiome research initiatives outside of the HMP over a ten-year period (fiscal years 2007–2016).

Application in cancer treatment

The gut microbiota has been linked to cancer and has been found to boost the efficacy of anticancer drugs. Resistance to chemo medicines or immune checkpoint inhibitors is linked to the altered gut microbiota, whereas supplementation with other bacterial species restores anticancer treatment responses. Altering the gut microbiota can improve the efficacy of anticancer medicines. Regardless of the important findings from preclinical models and clinical data from cancer patients, a better understanding of the microbiota’s interactions with cancer therapy can help researchers develop new cancer prevention strategies, stratify patients for more effective treatment, and reduce treatment complications.

Market Restraining Factors

Stringent government regulations

Probiotics have not been approved by the FDA as a live biotherapeutic product, which is a biological outcome instead of a vaccine that includes live organisms employed to prevent or cure a disease or condition in humans. However, there are FDA-regulated foods containing probiotics that are legally available, including dietary supplements, and these items cannot be sold to cure, treat, mitigate, or prevent any diseases. Probiotic supplements are heavily promoted in both retail stores and on the internet. Whereas the FDA has not yet approved any probiotics for therapeutic use, some are currently undergoing clinical trials and may soon be sold as biologics or other medications or would be exempted from sellable biological products. The existing FDA regulatory standards for probiotics are not tailored.

Product Outlook

Based on Product, the market is segmented into Drugs, Diagnostic Tests, Probiotics, Prebiotics, and Others. In 2021, the drugs segment acquired the largest revenue share of the human microbiome market. The growing number of human microbiome-based therapeutic products in clinical trials, as well as increased funding to develop microbiome-based medications, can be linked to the growth of this segment. Moreover, the increasing efficiency of human microbiome-based drugs is another factor that is propelling the growth of the segment.

Disease Type Outlook

Based on Disease Type, the market is segmented into Infectious Diseases, Endocrine & Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Others. In 2021, the gastrointestinal diseases segment recorded a significant reve3nue share of the human microbiome market. The increasing growth of this segment is attributed to the rising prevalence of gastrointestinal diseases. The phrase gastrointestinal disorders refer to any ailment or disease that affects the gastrointestinal tract. The gastrointestinal tract (also known as the GI tract) is a collection of hollow organs that run from the mouth to the stomach.

Technology Outlook

Based on Technology, the market is segmented into Genomics, Proteomics and Metabolomics. In 2021, the genomics segment procured the highest revenue share of the human microbiome market. A crucial driver for the genomics market is the growing number of initiatives financed by corporate and government entities. With the increasing number of government support initiatives, the growth of this segment is estimated to significantly surge during the forecast period. WGS (whole genome sequencing) is a method for examining complete genomes. Identifying inherited illnesses, defining the mutations that cause cancer progression, as well as tracking disease outbreaks have all benefited from genomic information.

Application Outlook

Based on Application, the market is segmented into Therapeutics and Diagnostics. In 2021, the diagnosis segment registered a substantial revenue share of the human microbiome market. The gut microbiota has the potential to be used as a diagnostic biomarker for HCC precancerous conditions, which is propelling the growth of this segment. The gut microbiome also serves as a diagnostic indicator for HCC. The oral microbiota has the potential to be used as a diagnostic biomarker for HCC precancerous conditions.

Type Outlook

Based on Type, the market is segmented into Microbiome Consortia Transplantation (FMT), Peptide, Live Biotherapeutic Product and Others. In 2021, the microbiome consortia transplantation (FMT) segment recorded the largest revenue share of the human microbiome market. The growth of this segment is attributed to the fact that recurrent Clostridium difficile infection can be successfully treated with FMT. The introduction of a solution of fecal material from a donor into the intestinal tract of a receiver in order to directly affect the recipient’s gut microbial composition and bestow a health benefit is known as fecal microbiota transplantation (FMT).

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 20212, North America accounted for the largest revenue share of the human microbiome market. The market in North America is being driven by factors such as the rising prevalence of lifestyle illnesses, rising awareness of preventative healthcare, the availability of financing for microbiome research, and the growing number of microbiome research and clinical activities.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Seres Therapeutics, Inc., 4D pharma plc, OptiBiotix Health Plc, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Ferring Holdings SA, and Enterome.

Scope of the Study

Market Segments covered in the Report:

By Product

• Drugs

• Diagnostic Tests

• Probiotics

• Prebiotics, and

• Others

By Disease Type

• Infectious Diseases

• Endocrine & Metabolic Disorders

• Gastrointestinal Diseases

• Cancer, and

• Others

By Technology

• Genomics

• Proteomics

• Metabolomics

By Application

• Therapeutics

• Diagnostics

By Type

• Microbiome Consortia Transplantation (FMT)

• Peptide

• Live Biotherapeutic Product

• Others

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific


o Brazil

o Argentina


o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Seres Therapeutics, Inc.

• 4D pharma plc

• OptiBiotix Health Plc

• Synlogic, Inc.

• Second Genome, Inc.

• Vedanta Biosciences, Inc.

• Finch Therapeutics Group, Inc.

• Ferring Holdings SA

• Enterome

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

North America Digestive Health Products Market Size, Share & Industry Trends Analysis Report By Type, By Ingredient, By Country and Growth Forecast, 2022 - 2028

  • $ 1500
  • July 2022
  • 82 pages

The North America Digestive Health Products Market would witness market growth of 7.2% CAGR during the forecast period (2022-2028). In western nations, probiotics, which are essential to sustaining a ...

  • North America
  • United States
  • Healthcare
  • Gut Health
  • Industry analysis
  • Overweight Prevalence
  • Disposable Income


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on